Literature DB >> 23074454

Bone morphogenetic proteins & spinal surgery for degenarative disc disease: an evidence-based analysis.

.   

Abstract

OBJECTIVE: This review is intended to summarize the evidence of safety and effectiveness of a recently licensed spinal fusion surgery device that includes a recombinant human bone morphogenetic protein (BMP). BONE MORPHOGENETIC PROTEINS: BMP are proteins that occur naturally in the matrix of human bone and stimulate bone growth. For spinal surgery, BMP must be delivered to the vertebral level where bone growth is desired. The BMP device currently available in Canada comprises a specific cage device and a bovine collagen sponge that delivers BMP. This sponge must be implanted in combination with this specific cage device from the same manufacturer. The device is marketed under the trade name INFUSE™ and provides an alternative to autologous bone graft in spinal fusion. REVIEW STRATEGY: Published literature identified through searches of MEDLINE and EMBASE was supplemented with material submitted by the device manufacturer as part of regulatory approval in the United States and available through the public access area of the website of the Food and Drug Administration. SUMMARY OF
FINDINGS: Evidence submitted to regulatory bodies in the USA and Canada indicates that the INFUSE™ device appears safe. The largest number of spinal fusion cases using BMP devices has been for anterior lumbar interbody fusion. Although radiologic fusion occurs at a consistently faster rate among recipients of the BMP device than among recipients of autologous bone grafts, clinical outcomes (pain and disability) appear no different. Regardless of technique, improvements in pain and disability are reported by similar proportions of participants in all the arms of all the trials. BMP devices for cervical fusion have yet to be approved in Canada but one small scale trial has reported radiologic fusion in all participants in both BMP and autologous bone graft arms and improvement in neck pain scores for all participants. BMP devices for lumbar fusion are licensed, safe and appear equivalent to autologous bone graft procedures for spinal fusion in terms of patient outcomes with the notable exception that patients undergoing autologous bone graft report pain at the donor site. Laparoscopic approaches yield reductions in postoperative length of stay compared to conventional open approaches.

Entities:  

Year:  2004        PMID: 23074454      PMCID: PMC3387739     

Source DB:  PubMed          Journal:  Ont Health Technol Assess Ser        ISSN: 1915-7398


  18 in total

1.  Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.

Authors:  Scott D Boden; James Kang; Harvinder Sandhu; John G Heller
Journal:  Spine (Phila Pa 1976)       Date:  2002-12-01       Impact factor: 3.468

2.  Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies.

Authors:  Ragnar Johnsson; Björn Strömqvist; Per Aspenberg
Journal:  Spine (Phila Pa 1976)       Date:  2002-12-01       Impact factor: 3.468

3.  Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages.

Authors:  J Kenneth Burkus; Matthew F Gornet; Curtis A Dickman; Thomas A Zdeblick
Journal:  J Spinal Disord Tech       Date:  2002-10

Review 4.  Recombinant human bone morphogenetic protein-2: use in spinal fusion applications.

Authors:  Harvinder S Sandhu; Safdar N Khan
Journal:  J Bone Joint Surg Am       Date:  2003       Impact factor: 5.284

5.  The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report.

Authors:  S D Boden; T A Zdeblick; H S Sandhu; S E Heim
Journal:  Spine (Phila Pa 1976)       Date:  2000-02-01       Impact factor: 3.468

6.  Purification and characterization of other distinct bone-inducing factors.

Authors:  E A Wang; V Rosen; P Cordes; R M Hewick; M J Kriz; D P Luxenberg; B S Sibley; J M Wozney
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  2001 Volvo Award Winner in Clinical Studies: Lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the Swedish Lumbar Spine Study Group.

Authors:  P Fritzell; O Hägg; P Wessberg; A Nordwall
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-01       Impact factor: 3.468

8.  The Oswestry low back pain disability questionnaire.

Authors:  J C Fairbank; J Couper; J B Davies; J P O'Brien
Journal:  Physiotherapy       Date:  1980-08       Impact factor: 3.358

9.  Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2.

Authors:  J Kenneth Burkus; Ensor E Transfeldt; Scott H Kitchel; Robert G Watkins; Richard A Balderston
Journal:  Spine (Phila Pa 1976)       Date:  2002-11-01       Impact factor: 3.468

10.  Chronic low back pain and fusion: a comparison of three surgical techniques: a prospective multicenter randomized study from the Swedish lumbar spine study group.

Authors:  Peter Fritzell; Olle Hägg; Per Wessberg; Anders Nordwall
Journal:  Spine (Phila Pa 1976)       Date:  2002-06-01       Impact factor: 3.468

View more
  1 in total

1.  Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount.

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2013-07-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.